Myasthenia gravis: Frequently asked questions

作者：John A. Morren, Yuebing Li · 发表于：Cleveland Clinic Journal of Medicine · 年份：2023 · DOI：10.3949/ccjm.90a.22017 · 被引用次数：34 · 研究领域：Myasthenia Gravis and Thymoma、Peripheral Neuropathies and Disorders、Parkinson's Disease and Spinal Disorders

Myasthenia gravis is a disorder of neuromuscular junction transmission, the result of antibodies against the post-synaptic aspect of the neuromuscular junction. Its clinical hallmark is fatigable weakness of skeletal muscles, which tends to vary in location and severity among patients. It is treated with pyridostigmine, immunotherapy, and thymectomy. Treatment is often individualized according to disease severity, antibody status, comorbidities, and other factors. This review uses a question-and-answer format to provide up-to-date, high-yield, clinically relevant information on myasthenia gravis.